High Growth Tech Stocks To Watch In December 2024

As global markets experience a wave of optimism, with U.S. small-cap indices like the Russell 2000 reaching new highs and broader indices maintaining strong upward momentum, investors are keenly observing how geopolitical developments and economic indicators might influence future trends. In this environment, identifying high-growth tech stocks involves looking for companies that not only demonstrate robust innovation but also have the resilience to navigate potential trade tensions and capitalize on consumer spending strength.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Material Group	20.45%	24.01%	★★★★★★
Ascelia Pharma	76.15%	47.16%	★★★★★★
Waystream Holding	22.09%	113.25%	★★★★★★
Pharma Mar	28.04%	56.19%	★★★★★★
Alnylam Pharmaceuticals	22.35%	70.33%	★★★★★★
TG Therapeutics	34.66%	56.98%	★★★★★★
Elliptic Laboratories	70.09%	111.37%	★★★★★★
Alkami Technology	21.89%	98.60%	★★★★★★
Travere Therapeutics	31.70%	72.51%	★★★★★★
Initiator Pharma	73.95%	31.67%	★★★★★★

Click here to see the full list of 1285 stocks from our High Growth Tech and AI Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Bonesupport Holding (OM:BONEX)

Simply Wall St Growth Rating: ★★★★★★

Overview: Bonesupport Holding AB (publ) is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across Europe, North America, and internationally, with a market cap of SEK23.72 billion.

Operations: Bonesupport generates revenue primarily from its pharmaceuticals segment, amounting to SEK814.46 million. The company focuses on developing and commercializing injectable bio-ceramic bone graft substitutes across various regions.

Bonesupport Holding's strategic emphasis on R&D is evident with a robust 34.9% year-over-year revenue growth, outpacing the Swedish market's modest 0.1% increase. This surge is underpinned by their innovative approach in medical solutions, particularly highlighted by the SOLARIO study results which demonstrated significant reductions in systemic antibiotic use through their products CERAMENT® G and CERAMENT® V. The company's financial health is further endorsed by an anticipated earnings growth of 74.3% annually, significantly above the market average of 15.1%. Recent executive changes and a notable transaction where Erik Selin acquired a 5.92% stake for SEK 1.3 billion underscore investor confidence and potential shifts in governance that could influence future strategy and market positioning.

• Click here to discover the nuances of Bonesupport Holding with our detailed analytical health report.

• Gain insights into Bonesupport Holding's historical performance by reviewing our past performance report.

Sinocelltech Group (SHSE:688520)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sinocelltech Group Limited is a biotech company focused on the research, development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China with a market cap of approximately CN¥17.28 billion.

Operations: The primary revenue stream for Sinocelltech Group comes from its Biological Drugs segment, which includes drugs and vaccines, generating approximately CN¥2.45 billion. The company's focus on biotechnology involves significant activities in the development and industrialization of recombinant proteins and monoclonal antibodies.

Sinocelltech Group has demonstrated a remarkable turnaround, with its recent financials showing a revenue leap to CNY 1.94 billion from CNY 1.38 billion year-over-year, alongside transitioning from a net loss to a net income of CNY 149.95 million. This growth is propelled by an aggressive R&D strategy, which is evident as the company's earnings are projected to surge by an impressive 139.27% annually. Their commitment to innovation is further underscored by their R&D expenses aligning closely with these advancements, ensuring they remain at the forefront of biotechnological developments in a fiercely competitive market.

• Delve into the full analysis health report here for a deeper understanding of Sinocelltech Group.

• Gain insights into Sinocelltech Group's past trends and performance with our Past report.

Chengdu Zhimingda Electronics (SHSE:688636)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Chengdu Zhimingda Electronics Co., Ltd. focuses on the research, development, production, and sale of military embedded computer module products in China, with a market cap of CN¥3.30 billion.

Operations: The company generates revenue primarily from the aerospace and defense sector, with a reported income of CN¥472.61 million. The business is centered on producing military embedded computer module products, reflecting its specialized focus within the industry.

Chengdu Zhimingda Electronics, amidst a challenging year with a significant revenue drop to CNY 208.66 million from CNY 399.05 million and a shift to a net loss of CNY 9.16 million, still shows potential given its strategic R&D investments and market forecasts. Despite recent setbacks, the company is positioned for recovery with projected earnings growth of 57.4% per year, outpacing the broader Chinese market's forecast of 26.1%. This focus on innovation could catalyze its rebound, especially as it navigates through the volatile tech landscape marked by its highly fluctuating share price over the past three months.

• Click to explore a detailed breakdown of our findings in Chengdu Zhimingda Electronics' health report.

• Review our historical performance report to gain insights into Chengdu Zhimingda Electronics''s past performance.

Key Takeaways

• Click this link to deep-dive into the 1285 companies within our High Growth Tech and AI Stocks screener.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com